Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Sepsis-associated coagulation disorders].

C-E Dempfle1

  • 1Universitätsklinikum Mannheim, I. Medizinische Klinik Theodor Kutzer Ufer 1-3, 68167 Mannheim. carl-erik.dempfle@med.ma.uni-heidelberg.de

Hamostaseologie
|June 1, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Point-of-care PT and aPTT in patients with suspected deficiencies of coagulation factors.

International journal of laboratory hematology·2016
Same author

Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines.

Journal of thrombosis and haemostasis : JTH·2013
Same author

[Pharmacology of the new oral anticoagulants].

Herz·2012
Same author

Anticoagulation in neurointerventions: basic pharmacology and pathophysiology, current status, practical advice.

Clinical neuroradiology·2012
Same author

Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine (Deutsche Interdisziplinäre Vereinigung für Intensiv- und Notfallmedizin (DIVI)).

German medical science : GMS e-journal·2010
Same author

[Prevention, diagnosis, treatment, and follow-up care of sepsis. First revision of the S2k Guidelines of the German Sepsis Society (DSG) and the German Interdisciplinary Association for Intensive and Emergency Care Medicine (DIVI)].

Der Anaesthesist·2010
Same journal

Update: Immune Tolerance Induction Practice in Haemophilia.

Hamostaseologie·2026
Same journal

Diagnosis and Management of Immune Platelet Transfusion Refractoriness.

Hamostaseologie·2026
Same journal

Too Common to Ignore: Decoding the Complexity of the FGG p.Ala108Gly Variant in Fibrinogen Disorders.

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
Same journal

Hamostaseologie·2026
See all related articles

Sepsis can cause dangerous bleeding due to low coagulation factors. Treatments like protein C concentrate and recombinant activated protein C show promise for severe sepsis and related purpura fulminans.

Area of Science:

  • Hematology
  • Critical Care Medicine
  • Infectious Diseases

Context:

  • Sepsis frequently involves coagulation activation and intravascular fibrin formation.
  • Consumption coagulopathy in sepsis presents with bleeding, often due to low coagulation factors from disseminated intravascular coagulation, plasma loss, or impaired liver synthesis.
  • Specific infections like meningococcal and pneumococcal can lead to sepsis-induced purpura fulminans, characterized by microvascular thrombosis and hemorrhage, with low plasma protein C levels as a key indicator.

Purpose:

  • To review the role of coagulation activation in sepsis and discuss therapeutic strategies.
  • To evaluate the efficacy of treatments such as protein C concentrate, recombinant activated protein C, heparin, and antithrombin concentrate in sepsis-induced coagulopathy and related conditions.

Summary:

Related Experiment Videos

  • Coagulation abnormalities are common in sepsis, leading to bleeding and conditions like purpura fulminans.
  • Treatment for sepsis-induced bleeding often involves substituting coagulation factors and platelets.
  • Recombinant activated protein C (Drotrecogin alfa, activated) has demonstrated benefits in sepsis-induced purpura fulminans and severe sepsis, particularly in patients with disseminated intravascular coagulation.

Impact:

  • Highlights the importance of understanding coagulation disorders in sepsis management.
  • Provides insights into the therapeutic potential of specific agents like Drotrecogin alfa, activated for severe sepsis and purpura fulminans.
  • Clarifies the limited role of general heparin or antithrombin concentrate use in sepsis outside specific indications.